Nanospacer

- Bringing nanofluidic technology to the people

About the technology

The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle characterisation. Nanofluidic technology, including analysis of proteins and binding events on a single-molecule level, will open doors to the next generation of nanomedicines, nanoparticles and nanomachinery.

Resources

  • Research Council Norway commercialisation grant
  • Patent pending
  • Prototypes ready for end-user testing
  • Norinnova as commercialisation partner

Value proposition

  • Simple to use
  • Broad application range
  • Affordable
  • Compatible with existing microscopes and workflows
Range of applications for the Nanospacer in life sciences and fluidic analytics

Image: Areas of applications

(1) drug screening

(2) exosome analysis

(3) nanofluidic cell cultures

(4) fertility testing

Opportunities for Collaboration

We are looking for end-users to test our Nanospacer concept. We are open to collaborate to ensure the Nanospacer meets your specific needs.

Partners

Universitetet i Tromsø

Inventor: Oliver Vanderpoorten

  • MSCA Fellow, Tromsø (NOR), EPSRC PhD in BioEng, Cambridge (UK), Background: electrical engineering, nanotechnology

Contact information

Thomas Seppola, Norinnova.
Foto: Marius Fiskum

Magnus Seppola

Forretningsutvikler | Tech Transfer

magnus@norinnova.no
Tlf. 951 12 385

Les om andre prosjekter:

mSpider

Motivating continous Sharing of Physical activity using non-Intrusive Data Extraction methods Retro- and prospectively About the technology Data collection of physical data …

Thyroid Assist

– A novel decision support aid tool (DST) for optimal levothyroxine dosage after thyroidectomy About the technology Levothyroxine is a necessary synthetic …

About the technology New and advanced label-free and super resolution microscopes and nanoscopes have emerged, and their characterization is becoming more demanding. …

Nanospacer

– Bringing nanofluidic technology to the people About the technology The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle …

A tool that predicts ice amount and distribution on marine structures About the technology Due to climate changes the Arctic marine territories …

CYMOPLIVE – Cyto-Motility and Cyto-Plasticity in Vitro Live-Cell Assay About the technology Cymoplive is a platform that allows us to study cells …

New therapeutic for liver disease, NASH

An unmet medical need

Non-alcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease that is expected to become the major cause of liver transplantation in the US by 2025. There is an enormous unmet medical need to treat the disease because of its high prevalence and lack of treatment options: there are currently no approved therapeutics for NASH.

Impact

Over 25% of adults worldwide have non-alcoholic fatty liver, and 10-30% of these people will progress to the more serious disease, NASH. Beyond lifestyle changes, there are no FDA approved therapeutic treatments for NASH.

The invention

We have a novel therapeutic approach to NASH based on a new understanding of disease-causing signalling pathways in the liver. Our approach reduces all 3 hallmarks of disease:

  • fat accumulation
  • fibrosis (liver scarring)
  • inflammation
Plan and commercial strategy

The project is currently supported by the Research Council of Norway, Novo Nordisk Foundation, and UiT – The Arctic University of Norway. Upon generation of proof-of-concept data, we plan to continue pre-clinical and clinical development through a spin-off company. We are seeking collaborations with the right partners to bring the project forward into pre-clinical and clinical development, including:

  • industry collaborations and partnerships
  • investors
Image: Treatment resulted in 41-58% reduction in all 3 disease characteristics in NASH mice.

Partners and collaborators

Universitetet i Tromsø

Contact information

Foto: Marius Fiskum

Bronwyn Smithies

Forretningsutvikler | Tech Transfer

bronwyn@norinnova.no
Tlf. 412 47 420

Les om andre prosjekter:

mSpider

Motivating continous Sharing of Physical activity using non-Intrusive Data Extraction methods Retro- and prospectively About the technology Data collection of physical data …

Thyroid Assist

– A novel decision support aid tool (DST) for optimal levothyroxine dosage after thyroidectomy About the technology Levothyroxine is a necessary synthetic …

About the technology New and advanced label-free and super resolution microscopes and nanoscopes have emerged, and their characterization is becoming more demanding. …

Nanospacer

– Bringing nanofluidic technology to the people About the technology The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle …

A tool that predicts ice amount and distribution on marine structures About the technology Due to climate changes the Arctic marine territories …

CYMOPLIVE – Cyto-Motility and Cyto-Plasticity in Vitro Live-Cell Assay About the technology Cymoplive is a platform that allows us to study cells …

Tau-on-Chip: nanofluidic amyloid aggregation within seconds

About the technology

On-demand production of protein aggregates: We produce oligomers and fibrils within seconds in a nanofluidic environment. This has potential for high throughput screening of drug candidates, automated in-vitro assays, and binding assays with single molecule sensitivity.

Areas of application

We envisage producing the nanofluidic Tau-on- Chip devices for use in drug development, clinical trials, research, and protein production.

Value proposition

  • Single molecule sensitivity.
  • For use in drug development, clinical trials, research, and protein production.
  • Patent pending.
 
Bilde microfluidic
Image: Microfluidic chips fabricated on glass slides.
Image: Induced fibrillation and oligomerization events in seconds.

Opportunities for Collaboration

We are looking for industry partners for collaboration and licensing. We are open to working together on the development of our Tau-on-Chip technology to accomodate your needs.

Resources and partners

Universitetet i Tromsø

The inventors:

Oliver Vanderpoorten

  • MSCA Fellow, Tromsø (NOR), EPSRC PhD in BioEng, Cambridge (UK), Background: electrical engineering, nanotechnology

Kevin Baumann

  • SNSF Swiss Postdoctoral Fellow, Basel (CH), PhD in Chemistry, Cambridge (UK), Background: biophysics, medical engineering

Contact information

Foto: Marius Fiskum

Ellen Dybdahl

Business developer

ellen@norinnova.no
Tlf. 974 79 260

Les om andre prosjekter:

mSpider

Motivating continous Sharing of Physical activity using non-Intrusive Data Extraction methods Retro- and prospectively About the technology Data collection of physical data …

Thyroid Assist

– A novel decision support aid tool (DST) for optimal levothyroxine dosage after thyroidectomy About the technology Levothyroxine is a necessary synthetic …

About the technology New and advanced label-free and super resolution microscopes and nanoscopes have emerged, and their characterization is becoming more demanding. …

Nanospacer

– Bringing nanofluidic technology to the people About the technology The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle …

A tool that predicts ice amount and distribution on marine structures About the technology Due to climate changes the Arctic marine territories …

CYMOPLIVE – Cyto-Motility and Cyto-Plasticity in Vitro Live-Cell Assay About the technology Cymoplive is a platform that allows us to study cells …

MicroRNAs for reduced bleeding risk in Venous thromboembolism patients

– MicroRNAs for risk assessment and treatment of venous thromboembolism

The challenge

Venous thromboembolism (VTE) is a highly prevalent disease, affecting around 1.1 million individuals in Europe each year, with 540,000 associated deaths. No modifiable risk-factors have been identified yet. The current anti-coagulant treatment is associated with serious bleeding risks. We therefore need to find a drug that prevents VTE without serious side affects.

Our approach

  •  Specific microRNAs associated with a higher risk of VTE were found
  • Targeted intervention of these microRNAs has the potential to effectively prevent VTE
  • Treatment of VTE with microRNA therapeutic without bleeding risk

Opportunities for Collaboration​

  • Searching for a collaborative R&D deal with industrial partner
  • Looking for a pharmaceutical partner with the expertise, commitment and financial strength to take it through the clinical phase and into the market.

Results

  • Population study

A pilot and a validation study show that specific miRNAs can be potential predictors of VTE and the risk of VTE is highly associated with miRNA level.

  • In-vivo mouse model for venous thrombosis

The addition of a specific miRNA show reduction in thrombose size in a in-vivo mouse model

  • Patent application for the technology is filed
Figure: VTE is a serious and common disease, 40% of cases accors spontanously with unknown cause.

Collaboration partners

Universitetet i Tromsø
norinnova logo. Ikon.

Contact information

Foto: Marius Fiskum / www.mariusfiskum.no

Morten Elde

Forretningsutvikler | Tech Transfer

morten@norinnova.no
Tlf. 414 06 762

Les om andre prosjekter:

mSpider

Motivating continous Sharing of Physical activity using non-Intrusive Data Extraction methods Retro- and prospectively About the technology Data collection of physical data …

Thyroid Assist

– A novel decision support aid tool (DST) for optimal levothyroxine dosage after thyroidectomy About the technology Levothyroxine is a necessary synthetic …

About the technology New and advanced label-free and super resolution microscopes and nanoscopes have emerged, and their characterization is becoming more demanding. …

Nanospacer

– Bringing nanofluidic technology to the people About the technology The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle …

A tool that predicts ice amount and distribution on marine structures About the technology Due to climate changes the Arctic marine territories …

CYMOPLIVE – Cyto-Motility and Cyto-Plasticity in Vitro Live-Cell Assay About the technology Cymoplive is a platform that allows us to study cells …